Prelude Therapeutics PRLD
NASDAQ PRLD
$3.76 +0.16 (+4.44%)
At close: Nov 9, 2026 · 4:00 PM EST

Prelude Therapeutics (PRLD) Non-Current Deferred Revenue (2025)

Updated

Prelude Therapeutics' Non-Current Deffered Revenue was $1.8 million in Q4 2025.

Analysis

Prelude Therapeutics (PRLD) Non-Current Deferred Revenue (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,261.99 Bn 1,235.61 Bn 20.46 Bn
2 Johnson & Johnson 678.93 Bn 598.79 Bn 17.30 Bn
3 AbbVie 518.29 Bn 486.30 Bn 13.12 Bn
4 Merck 365.98 Bn 328.92 Bn 13.19 Bn
5 Novartis Ag 316.85 Bn 290.09 Bn -
6 Astrazeneca 293.40 Bn 267.29 Bn 13.26 Bn
7 Amgen 251.78 Bn 203.43 Bn 7.58 Bn
8 Gilead Sciences 210.61 Bn 185.71 Bn 6.73 Bn
9 Pfizer 166.87 Bn 114.23 Bn 12.56 Bn
10 Prelude Therapeutics 366.99 Mn -230.31 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 1.80 Mn
API Access

Prelude Therapeutics Non-Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=PRLD&period=max&api_key=YOUR_API_KEY